 |
||
 |
 |
 |
 |
||
Our strategy
We are building a portfolio of novel programmes in cancer, spanning early stage discovery up to early clinical trials, through a combination of in-house discovery and in-licensing.
We seek to retain ownership of our key programmes until we have demonstrated proof of concept in man, and to identify potential partners for non-core programmes at an earlier stage. However we have a very flexible approach to partnering and deal structures, and are happy to entertain partnering discussions on any of our programmes at any time.
In-licensing
We are interested in talking to academic and industry collaborators who have novel, small molecule cancer programmes for which they are seeking partners.
Out-licensing
We are currently interested in talking to potential partners about a collaboration on our Redox Homeostasis Modulators programme in the field of tuberculosis.
Conference attendance
We regularly attend key academic and industry life sciences conferences. Please click here for information about Pharminox attendance at specific events.
